FinTechFunding

Immutep: Shares positive data from phase 2b AIPAC trial

Immutep Shares positive data from phase 2b AIPAC trial

  • Immutep (IMM) sees a significant increase in innate and adaptive immune response biomarkers in its phase IIb AIPAC trial
  • The trial evaluated efti combined with paclitaxel chemotherapy compared to a placebo group in 227 patients with HER2-negative/HR-positive metastatic breast cancer
  • IMM says the higher immune response in efti patients compared to placebo patients confirms efti is activating the immune system and improving overall survival
  • The company is a globally active biotechnology company that is a leader in developing LAG-3 related immunotherapeutic products
  • The company is trading 7.58 per cent higher at 35.5 cents
Previous article
Intigriti: Raises Over €21.13M in Series B Funding
Next article
Elixir Energy: Completes Tim-2 well in Mongolia
Steve Sam
Steve Sam
Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

You May Also Like

FinTech

Lloyds Tests Quantum Computing to Strengthen Fraud Detection

The bank explores advanced tech to tackle money mule networks effectively.Highlights: Lloyds is experimenting with quantum computing for...
FinTech

9fin Secures $170 Million Raise, Valued at $1.3 Billion

The fintech platform enhances its funding to accelerate growth and innovation.Highlights: 9fin raised $170 million in a recent...
FinTech

CommBank Enhances Account Onboarding with Password Chip Scanning

New feature streamlines account setup via mobile app for users.Highlights: CommBank introduces password chip scanning in its mobile...
FinTech

Coinbase Receives Conditional Approval for National Trust Bank Charter

The approval marks a significant step for Coinbase in the financial sector.Highlights: Coinbase secures conditional approval for a...